SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 257.4 INR | -5.00% |
|
-22.61% | -10.27% |
| Sales 2022 | 1.37B 16.46M 22.51M | Sales 2023 | 2.39B 28.64M 39.16M | Capitalization | 58.2B 698M 954M |
|---|---|---|---|---|---|
| Net income 2022 | -2.03B -24.4M -33.35M | Net income 2023 | -2.23B -26.7M -36.5M | EV / Sales 2022 | 59.3 x |
| Net Debt 2022 | 663M 7.95M 10.88M | Net cash position 2023 | 3.87B 46.39M 63.43M | EV / Sales 2023 | 22.8 x |
| P/E ratio 2022 |
-38.4
x | P/E ratio 2023 |
-22.9
x | Employees | 407 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 25.39% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sun Pharma Advanced Research Company Limited
More press releases
| 1 day | -5.00% | ||
| 1 week | -22.61% | ||
| Current month | -30.12% | ||
| 1 month | -30.84% | ||
| 3 months | -30.87% | ||
| 6 months | +12.72% | ||
| Current year | -10.27% |
1 week
257.35
315.95
1 month
257.35472.80
Current year
257.35472.80
1 year
178.80472.80
3 years
162.10472.80
5 years
81.00472.80
10 years
81.00598.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 14-04-23 | |
Chetan Rajpara
DFI | Director of Finance/CFO | - | 17-01-31 |
| Chairman | 68 | 06-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 68 | 06-02-28 | |
| Director/Board Member | 67 | 06-02-28 | |
| Director/Board Member | 70 | 14-10-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 257.4 | -5.00% | 592,866 |
| 24-04-25 | 270.9 | -5.00% | 14,322,210 |
| 24-04-24 | 285.2 | -5.00% | 216,781 |
| 24-04-23 | 300.2 | -5.00% | 119,875 |
| 24-04-22 | 316 | -4.99% | 92,823 |
Delayed Quote NSE India S.E., April 26, 2024 at 07:43 am
More quotes
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage bio-pharmaceutical company. The Company is in the business of research and development (R&D) of pharmaceutical products to unmet medical needs in the areas of oncology, neurodegeneration and immunology. The Company develops New Chemical Entities (NCE), New Biological Entities and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its Novel Drug Delivery Systems (NDDS) include Wrap Matrix Technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology is useful to develop controlled release tablets. It has developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. It has also developed Xelpros, a BAK free latanoprost eye drop developed using Lipexelle technology. Xelpros is commercialized by its partner in the United States. It has also developed PDP-716 eye drops for treatment of Glaucoma based on its TearAct technology.
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -10.27% | 1B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- SPARC Stock
